Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROpel: Olaparib Plus Abiraterone in First-line mCRPC
NCT05171816Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing olaparib plus abiraterone with placebo plus abiraterone (2 arms). Primary endpoint: Radiological Progression Free Survival up to 913 days. Started Jun 2021; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05171816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171816.